Skip to content

13F-HR filed by Octagon Capital Advisors LP

Octagon Capital Advisors LP filed this 13F-HR for the quarter ended 2022-12-31, filed 2023-02-14, with 32 holding rows worth $642,219,944.

Accession
0001214659-23-002379
Filed
2023-02-14
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q4 2022

A holdings report, 32 entries on the cover page, a total value of $642,219,944 stated on the cover page (in dollars after the unit check, H1), rows summing to $642,219,944 with VALUE read as dollars as filed, 13F file number 028-20958. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
APELLIS PHARMACEUTICALS INC03753U106COM3,160,000$163,403,600dollars as filed
CHINOOK THERAPEUTICS INC16961L106COM2,551,703$66,854,619dollars as filed
VERONA PHARMA PLC925050106SPONSORED ADS2,468,000$64,488,840dollars as filed
ARCUS BIOSCIENCES INC03969F109COM2,482,700$51,342,236dollars as filed
MIRATI THERAPEUTICS INC60468T105COM750,000$33,982,500dollars as filed
CELLDEX THERAPEUTICS INC NEW15117B202COM NEW761,398$33,935,509dollars as filed
IVERIC BIO INC46583P102COM1,278,000$27,361,980dollars as filed
VIRIDIAN THERAPEUTICS INC92790C104COM824,200$24,074,882dollars as filed
TANDEM DIABETES CARE INC875372203COM NEW474,929$21,348,059dollars as filed
AEROVATE THERAPEUTICS INC008064107COM621,712$18,216,162dollars as filed
SPDR SER TR78464A870S&P BIOTECH199,417$16,551,611dollars as filed
VERA THERAPEUTICS INC92337R101COMMON STOCK665,156$12,870,769dollars as filed
INTRA-CELLULAR THERAPIES INC46116X101COMMON STOCK220,953$11,692,833dollars as filed
CYMABAY THERAPEUTICS INC23257D103COM1,859,200$11,657,184dollars as filed
4D MOLECULAR THERAPEUTICS INC COM35104E100Stock499,996$11,104,911dollars as filed
ALPINE IMMUNE SCIENCES INC02083G100COM1,225,000$9,003,750dollars as filed
ITEOS THERAPEUTICS INC46565G104COM445,000$8,690,850dollars as filed
VIKING THERAPEUTICS INC92686J106COM870,500$8,182,700dollars as filed
AVIDITY BIOSCIENCES INC COM05370A108Stock324,629$7,203,518dollars as filed
BRIDGEBIO PHARMA INC10806X102COM933,743$7,115,122dollars as filed
STOKE THERAPEUTICS INC86150R107COM763,456$7,046,699dollars as filed
Xilio Therapeutics Inc.98422T100COM2,425,000$6,523,250dollars as filed
89BIO INC282559103COM380,000$4,837,400dollars as filed
GOSSAMER BIO INC COM38341P102Stock1,958,069$4,249,010dollars as filed
MIRUM PHARMACEUTICALS INC604749101COM100,000$1,950,000dollars as filed
PRAXIS PRECISION MEDICINES I74006W108COM800,000$1,904,000dollars as filed
DEXCOM INC COM252131107Stock15,000$1,698,600dollars as filed
PROMETHEUS BIOSCIENCES INC74349U108COM15,000$1,650,000dollars as filed
JOUNCE THERAPEUTICS INC481116101COM1,400,000$1,554,000dollars as filed
MEREO BIOPHARMA GROUP PLC589492107CMN1,000,000$750,000dollars as filed
NUVALENT INC COM670703107Stock25,000$744,500dollars as filed
CENTURY THERAPEUTICS INC15673T100COM45,000$230,850dollars as filed

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001214659-23-002379this filing2023-02-14acceptance time not in the bulk data set